KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer
CELEBRATION, Fla., Jan. 11, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS) disorders, neurodegenerative diseases, lysosomal storage disorders and related treatment areas, announced the promotions of Sven Guenther, Ph.D., to Chief Scientific Officer, and Christal M.M. Mickle, M.A., to Chief Product Development Officer. Ms. Mickle, a co-founder of KemPharm, and Dr. Guenther have been members of KemPharm’s leadership team since the early days of the Company.
- Mickle, M.A., to Chief Product Development Officer.
- Ms. Mickle, a co-founder of KemPharm, and Dr. Guenther have been members of KemPharm’s leadership team since the early days of the Company.
- Dr. Guenther was one of the first members of KemPharm, most recently serving as the company’s Executive Vice President of Research and Development.
- As Chief Scientific Officer, he will continue to lead KemPharm’s research team and play a central role in the advancement of the company’s pipeline.